PT - JOURNAL ARTICLE AU - Cao, Min AU - Zhang, Dandan AU - Wang, Youhua AU - Lu, Yunfei AU - Zhu, Xiangdong AU - Li, Ying AU - Xue, Honghao AU - Lin, Yunxiao AU - Zhang, Min AU - Sun, Yiguo AU - Yang, Zongguo AU - Shi, Jia AU - Wang, Yi AU - Zhou, Chang AU - Dong, Yidan AU - Peng, Longping AU - Liu, Ping AU - Dudek, Steven M. AU - Xiao, Zhen AU - Lu, Hongzhou TI - Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China AID - 10.1101/2020.03.04.20030395 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.04.20030395 4099 - http://medrxiv.org/content/early/2020/03/06/2020.03.04.20030395.short 4100 - http://medrxiv.org/content/early/2020/03/06/2020.03.04.20030395.full AB - Background Since mid-December 2019, a cluster of pneumonia-like diseases caused by a novel coronavirus, now designated COVID-19 by the WHO, emerged in Wuhan city and rapidly spread throughout China. Here we identify the clinical characteristics of COVID-19 in a cohort of patients in Shanghai.Methods Cases were confirmed by real-time RT-PCR and were analysed for demographic, clinical, laboratory and radiological features.Results Of 198 patients, the median duration from disease onset to hospital admission was 4 days. The mean age of the patients was 50.1 years, and 51.0% patients were male. The most common symptom was fever. Less than half of the patients presented with respiratory systems including cough, sputum production, itchy or sore throat, shortness of breath, and chest congestion. 5.6% patients had diarrhoea. On admission, T lymphocytes were decreased in 45.8% patients. Ground glass opacity was the most common radiological finding on chest computed tomography. 9.6% were admitted to the ICU because of the development of organ dysfunction. Compared with patients not treated in ICU, patients treated in the ICU were older, had longer waiting time to admission, fever over 38.5° C, dyspnoea, reduced T lymphocytes, elevated neutrophils and organ failure.Conclusions In this single centre cohort of COVID-19 patients, the most common symptom was fever, and the most common laboratory abnormality was decreased blood T cell counts. Older age, male, fever over 38.5°C, symptoms of dyspnoea, and underlying comorbidity, were the risk factors most associated with severity of disease.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialHistologic featuresFunding StatementFunding information: This research was funded by the First-rate University and Discipline Construction Project of Fudan University (IDF162005) and the Key Scientific Research Projects on 2019-nCoV of Shanghai Public Health Clinical Centre (2020YJKY01), the Special Emergency Project for the Prevention and Treatment of COVID-19 with Traditional Chinese Medicine in Shanghai（2020NCP001）, and the 2018-2020 Three-year Action Plan for Traditional Chinese Medicine Further Development in Shanghai (ZY (2018-2020) CCCX-2002-04).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon request. Participant data are without names and identifiers, and they will be made available after approval from the corresponding author and National Health Commission. After publication of study findings, the data will be available for others to request. The research team will provide an email address for communication once the data are approved for sharing.